arrow
A

Aya Kuchiba

national cancer center institute for cancer control
H指数:47
被引数:9,533

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Glycemic index, glycemic load, and colorectal cancer risk stratified by insulin receptor expression: the Japan Public Health Center-based Prospective study

血糖指数、血糖负荷及按胰岛素受体表达分层的结直肠癌风险:日本公共卫生中心为基础的前瞻性研究

2026-06-190
PRE
Impact of a provider-level incentive on smoking cessation treatment use: A secondary dataset analysis using administrative claims data and a cross-sectional survey in Japanese health check-up settings (N-EQUITY2203 )

提供者层面激励对戒烟治疗使用的影响:基于日本健康检查设置中行政索赔数据和横断面调查的二次数据集分析(N-EQUITY2203)

2026-05-010
OA
Factors associated with awareness, reading and perceptions of clinical practice guidelines among the general population in Japan: A nationwide cross-sectional survey (INFORM Study 2023)

日本普通人群中与临床实践指南的认知、阅读和感知相关的因素:一项全国性横断面调查(INFORM研究2023)

2026-02-120
PRE
Associations Between Obesity, Diabetes Mellitus, and Pancreatic Cancer in the Japanese Population: A Mendelian Randomization Study

日本人群中肥胖、糖尿病和胰腺癌的关联性研究:一项孟德尔随机化研究

2026-02-010
OAAI
Identification and prognostic value of non-hotspot POLE exonuclease domain mutations in endometrial cancer

子宫内膜癌中非热点POLE外切酶域突变的鉴定及其预后价值

2026-01-010
OAAI
Germline variants of the POLH and RAD51 genes are candidate variants associated with risk of hormone receptor-negative young-onset breast cancer

POLH和RAD51基因的种系变异是激素受体阴性年轻发病乳腺癌风险的候选变异。

2025-11-280
OAAI
Response to the letter to the editor: Commentary on “Association between plasma 25-hydroxyvitamin D concentration and incident disabling dementia risk in Japan: A case-cohort study”

对致编辑信件的回应:对“日本血浆25-羟基维生素D浓度与新增致残性痴呆风险之间的关联:一项病例-队列研究”的评论

2025-11-220
PRE
Prediction recurrence in stage I epidermal growth factor receptor-mutated non-small cell lung cancer using multi-modal data

基于多模态数据的I期表皮生长因子受体突变非小细胞肺癌的预测复发

2025-08-250
PREAI
Genomic profiles of pathogenic and moderate-penetrance germline variants associated with risk of early-onset lung adenocarcinoma

与早发性肺腺癌风险相关的致病性和中等外显率生殖细胞系变异的基因组特征

2025-06-150
OAAI
A phase 3 study (PATHWAY) of palbociclib plus tamoxifen in patients with HR-positive/HER2-negative advanced breast cancer
2024-08-220
OA
Clonal Architecture of circulating tumor DNA predicts Early Progression on Tamoxifen With or Without Palbociclib in Hormone Receptor-Positive Advanced Breast Cancer: NCCH1607/PATHWAY trial
2024-05-020
PRE